Abstract
A surveillance system for sales volumes of antimicrobial agents for veterinary use was established in Germany in 2011. Since then, pharmaceutical companies and wholesalers have been legally obliged to report annual volumes of veterinary antimicrobial products sold to veterinary practices or clinics located in Germany. The evaluation of sales volumes for eight consecutive years resulted in a considerable total decrease by 58% from 1706 tons to 722 tons. During the investigation period, two legally binding measures to control the risk of antimicrobial resistance resulting from the veterinary use of antimicrobials were introduced, a) the German treatment frequencies benchmarking in 2014 and b) the obligation to conduct susceptibility testing for the use of cephalosporins of the 3rd and 4th generation and of fluoroquinolones in 2018. Both had a marked impact on sales volumes. Nonetheless, the category of Critically Important Antimicrobials as defined by the World Health Organization kept accounting for the highest share on sales volumes in Germany in 2018 with 403 tons, despite an overall reduction by 53%. Sales surveillance is considered essential for data retrieval on a global scale and inter-country comparison. However, the usability of a surveillance system based on sales data for risk management of antimicrobial resistance has limitations. The German system does not include off-label use of antimicrobial products authorized for human medicine and does not allow for identification of areas of high risk according to animal species, farm and production types and indications for treatment. For further reduction and enhanced promotion of a prudent use of antimicrobials, targeted measures would be required that could only be deducted from use data collected at farm or veterinary practice level. A surveillance system based on use data is currently lacking in Germany but will be established according to Regulation (EU) 2019/6 on veterinary medicinal products.
Highlights
Antimicrobials are invaluable agents in combating bacterial infectious diseases in humans and animals
The aim of this article is to present the development of sales volumes of antimicrobials for veterinary use in Germany according to the World Health Organization (WHO) prioritization for eight consecutive years, to examine the impact of regulatory interventions and to discuss assets and drawbacks of a surveillance system based on sales data
The evaluation of data collected by the German sales surveillance system for eight consecutive years determined a considerable reduction of sales volumes of antimicrobial agents for veterinary use by 58%
Summary
Antimicrobials are invaluable agents in combating bacterial infectious diseases in humans and animals. Pathogenic bacterial species that acquired multidrug resistance (defined as acquired non-susceptiblity to at least one agent in three or more antimicrobial classes [1]), pose a health risk in particular. As a consequence of multidrug resistance, certain antimicrobials can become one of a few treatment alternatives or even the sole remaining therapeutic option for severe bacterial infections [2,3,4,5,6,7,8]. The majority of antimicrobial classes ranked as CIAs but of High Priority, are solely authorized as human medicinal products in Germany. Only one antimicrobial class is exclusively authorized as veterinary medicinal product in Germany, the ionophores. It is administered prepartum to individual animals that are at high risk for ketosis and considered to comprise a minor proportion of antimicrobial consumption in dairy cows. The use of antimicrobials for growth promotion is prohibited in all Member States of the European Union (EU) since 2006 [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
